The 1st. TBAP Innovation Contest

AquaTex wins TBAP Grand Prize
The first TBAP Innovation Contest (“The Contest”) was held on Friday, August 6, 2021. From all teams that participated in the Triple Bridge Acceleration Program and its Review Meetings, 7 individuals/teams (8 research topics) were selected to participate in The Contest and present their Life Sciences research, focusing on their plans for social implementation. Each presentation was evaluated by a board of judges comprised of TBAP Advisors and TBAP Corporate members. Several US Venture Capitalists were invited as special guests and participated in the review process.
The TBAP Grand Prize was awarded to AquaTex Medical for their research on the “Development of Novel Liquid Embolic Material for Neuro-interventional Treatment”. AquaTeX Medical is led by CEO, Dr. Ichiro Yuki, a Clinical Associate Professor at UCI Medical Center, joined by, Dr. Shuichi Suzuki and Dr. Frank P.K.Hsu, both whom are neuro-interventionalists and professors at UCI Medical Center, and Dr. Kousaku Ohkawa, a polymer scientist and Professor at Shinshu University. The team is developing a low-risk (cytotoxicity, catheter entrapment) liquid embolic material to treat Vascular malformation.

- TBAP Grand Prize

Ichiro Yuki, MD (AquaTex)
University of California, Irvine
“Development of Novel Liquid Embolic Material for Neuro-interventional Treatment”

- TBAP Prize

Kenichi Kokubo, Ph.D. (Physiologas Technologies)
Kitasato University, School of Allied Health Sciences
“Portable hemodialysis machine for in-home therapy / New gas inhalation therapy to treat myocardial infarction”
Other Presenters
  • Kiminobu Sugaya, Ph.D. (Progenicyte Japan) / University of Central Florida
    “Small molecule to increase endogenous stem cells and neurogenesis”
  • Hidenori Matsui, Ph.D. / Kitasato University, Omura Satoshi Memorial Institute
    “Prevention of malignant tumor and Parkinson’s disease by eradication of Helicobacter suis”
  • Kazuo Miyazaki, M.S. (MiCAN Technologies)
    “High precision artificial blood cells for various types of evaluation of drugs, using iPS cell technology”
  • Takashi Fukuyama, Ph.D. / Kitasato Medical Center
    “Novel therapeutic technology for triple negative breast cancer”
  • Yosuke Uchiyama, Ph.D. / Kitasato University, School of Science
    “Cancer Cell Imaging by 9AA Fluorescence Method”